BioLife Solutions, Inc. Proceeds from Lines of Credit
BioLife Solutions, Inc. (BLFS) reported Proceeds from Lines of Credit of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2024-02-29
- BioLife Solutions, Inc. proceeds from lines of credit for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- BioLife Solutions, Inc. proceeds from lines of credit for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- BioLife Solutions, Inc. proceeds from lines of credit for the quarter ending 2021-12-31 was $856.00K.
- BioLife Solutions, Inc. proceeds from lines of credit for the quarter ending 2021-09-30 was $14.65M.
- BioLife Solutions, Inc. proceeds from lines of credit for fiscal 2023 was $0.00.
- BioLife Solutions, Inc. proceeds from lines of credit for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- BioLife Solutions, Inc. proceeds from lines of credit for fiscal 2021 was $27.31M.
- BioLife Solutions, Inc. proceeds from lines of credit for fiscal 2020 was $0.00.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-29 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-09 | |||
| 2021-12-31 | $856.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $15.51M derived: sum of 2 quarters · filed 2024-02-29 | $27.31M 10-K · filed 2024-02-29 | |
| 2021-09-30 | $14.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $26.45M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $11.80M 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-16 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B |